Morgan Stanley Xtl Biopharmaceuticals LTD Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Xtl Biopharmaceuticals LTD stock. As of the latest transaction made, Morgan Stanley holds 10,011 shares of XTLB stock, worth $9,210. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,011

Previous 11,011 9.08%

Holding current value

$9,210

Previous $12,000 8.33%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.11 - $1.82 $1,110 - $1,820	-1,000 Reduced 9.08%	10,011 $11,000
Q2 2025 Aug 15, 2025	SELL	$0.95 - $1.53 $2,128 - $3,427	-2,240 Reduced 16.9%	11,011 $12,000
Q1 2025 May 15, 2025	SELL	$1.1 - $2.09 $5,610 - $10,659	-5,100 Reduced 27.79%	13,251 $15,000
Q4 2024 Feb 14, 2025	SELL	$1.32 - $2.4 $10,692 - $19,440	-8,100 Reduced 30.62%	18,351 $35,000
Q3 2024 May 14, 2025	SELL	$2.16 - $2.98 $14,472 - $19,966	-6,700 Reduced 20.21%	26,451 $63,000

Q3 2024 Nov 14, 2024	SELL	$2.16 - $2.98 $14,472 - $19,966	-6,700 Reduced 20.21%	26,451 $63,000
Q2 2024 May 14, 2025	BUY	$2.04 - $3.33 $30,192 - $49,284	14,800 Added 80.65%	33,151 $80,000
Q2 2024 Oct 17, 2024	SELL	$2.04 - $3.33 $12,280 - $20,046	-6,020 Reduced 15.37%	33,151 $80,000
Q2 2024 Aug 14, 2024	SELL	$2.04 - $3.33 $12,280 - $20,046	-6,020 Reduced 15.37%	33,151 $80,000
Q1 2024 Oct 17, 2024	BUY	$0.8 - $3.07 $4,816 - $18,481	6,020 Added 18.16%	39,171 $110,000
Q1 2024 Aug 16, 2024	SELL	$0.8 - $3.07 $480 - $1,842	-600 Reduced 1.51%	39,171 $110,000
Q1 2024 May 15, 2024	SELL	$0.8 - $3.07 $480 - $1,842	-600 Reduced 1.51%	39,171 $110,000
Q4 2023 Aug 16, 2024	BUY	$0.76 - $1.13 $5,031 - $7,480	6,620 Added 19.97%	39,771 $40,000
Q4 2023 Feb 13, 2024	SELL	$0.76 - $1.13 $608 - $903	-800 Reduced 1.97%	39,771 $40,000
Q3 2023 Nov 15, 2023	SELL	$0.77 - $1.05 $462 - $630	-600 Reduced 1.46%	40,571 $36,000
Q2 2023 Aug 14, 2023	SELL	$0.99 - $1.37 $594 - $822	-600 Reduced 1.44%	41,171 $41,000
Q1 2023 May 15, 2023	SELL	$1.17 - $1.42 $1,404 - $1,704	-1,200 Reduced 2.79%	41,771 $54,000
Q4 2022 Feb 14, 2023	SELL	$1.04 - $1.48 $2,392 - $3,404	-2,300 Reduced 5.08%	42,971 $51,000
Q3 2022 Nov 14, 2022	SELL	$1.11 - $1.79 $3,885 - $6,265	-3,500 Reduced 7.18%	45,271 $50,000
Q2 2022 Oct 27, 2022	SELL	$1.38 - $2.4 $690 - $1,200	-500 Reduced 1.01%	48,771 $74,000
Q2 2022 Aug 15, 2022	SELL	$1.38 - $2.4 $690 - $1,200	-500 Reduced 1.01%	48,771 $74,000
Q1 2022 Oct 27, 2022	BUY	$2.13 - $2.91 $1,065 - $1,455	500 Added 1.03%	49,271 $102,000
Q1 2022 May 13, 2022	SELL	$2.13 - $2.91 $3,834 - $5,238	-1,800 Reduced 3.52%	49,271 $102,000
Q4 2021 Feb 14, 2022	SELL	$2.63 - $4.41 $1,578 - $2,646	-600 Reduced 1.16%	51,071 $141,000
Q3 2021 Nov 15, 2021	BUY	$3.43 - $5.2 $177,231 - $268,689	51,671 New	51,671 $226,000

Others Institutions Holding XTLB

# of Institutions

Shares Held

426K

Call Options Held

Put Options Held

View Full List

About XTL BIOPHARMACEUTICALS LTD

Ticker XTLB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,449,060
Market Cap $5.01M
Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...

More about XTLB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account